Phase 1 clinical trial evaluating LM-299 for advanced solid tumors
Latest Information Update: 26 Oct 2024
At a glance
- Drugs LM 299 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors LaNova Medicines Limited
- 23 Oct 2024 New trial record